Harnessing the regenerative capacity of keratinocytes and fibroblasts from human skin has created new opportunities to develop cell-based therapies for patients. Cultured cells and bioengineered skin products are being used to treat patients with inherited and acquired skin disorders associated with defective skin, and further clinical trials of new products are in progress. The capacity of extracutaneous sources of cells such as bone marrow is also being investigated for its plasticity in regenerating skin, and new strategies, such as the derivation of inducible pluripotent stem cells, also hold great promise for future cell therapies in dermatology. This article reviews some of the preclinical and clinical studies and future directions relating to cell therapy in dermatology, particularly for inherited skin diseases associated with fragile skin and poor wound healing.
O ne of the key functions of skin is to provide a mechanical barrier against the external environment. In several inherited and acquired dermatological disorders, however, this resilience is broken. Loss of a functional epidermis can have profound biological and clinical consequences including loss of water and electrolytes, cutaneous and systemic infections, as well as impaired thermoregulation. Epidermal failure can occur from burns, trauma, and adverse drug reactions. Several inherited diseases associated with inherent mechanical weaknesses in epidermal or dermal structural proteins can all be associated with extensive skin wounds and chronic erosions. Ulceration of the skin caused by common pathologies such as venous hypertension, arterial impairment, diabetes mellitus, or neuropathies creates an enormous clinical and health economic burden. Therapeutic interventions to restore an intact epithelium and recover skin function have therefore been an important long-term focus of both traditional and translational medicine, and one in which a number of key advances and clinical benefits have occurred in recent years.
Cell therapy to repair or restore a defective epithelium and possibly deeper skin layers represents an attractive area of translational research that could have significant health benefits for many people. In this review, we discuss the development and application of cell therapy in dermatology, with a special focus on inherited skin disorders in which chronic ulceration has a major impact on quality of life. The main emphasis of the text is on recent clinical studies as well as new and emerging strategies that can exploit and harness the regenerative potential of human cells to restore skin tissue, although an overview of the clinical applications of cell therapy across a range of skin diseases is presented in Table 1 . With regard to the focus of this review, it is hoped that cell therapy lessons learned from studies on rare skin diseases will also be relevant to improving future healthcare of patients with more common disorders associated with defective skin.
KERATINOCYTE CULTURE AND SKIN GRAFTING
In 1975, the discovery by Rheinwald and Green (1975) that keratinocytes could be cultured in vitro and the subsequent work that showed the enzyme dispase could help create sheets of cells suitable for grafting (Green et al. 1979) led to radical new options for clinical translation, including the treatment of burns patients (O' Connor et al. 1981) . Notably, a small piece of skin ( 2 cm 2 ) could be grown into sheets of epithelium, or cultured keratinocyte grafts that were suitable for treating wounds. Serial subculture enabled rapid expansion of the keratinocytes, such that grafts of a total area equivalent to that of the surface of an adult could be obtained in ,1 mo. Thereafter, the development of composite skin grafts, including a dermal component such as de-epidermized cadaveric dermis, biopolymers, or artificial scaffolds allowed for further refinement of cultured skin for clinical use (Ojeh et al. 2001; Auger et al. 2004 ). Cultured epidermal grafts have been shown to promote re-epithelialization in some genetic skin diseases associated with chronic wounds (Schofield et al. 1990; Hill et al. 1992; McGrath et al. 1993; Roseeuw et al. 1994) , although success has been limited mainly because of the high risk of graft infection.
Newer devices, including cell spray formulations (following digestion of small pieces of skin with trypsin) that can contain keratinocytes, melanocytes, Langerhans cells, and fibroblasts have also been developed (Gravante et al. 2007 ) and used in clinical trials to augment wound healing (Kirsner et al. 2012) . In addition, the use of noncutaneous cells, such as bone marrow (BM) cells, has been explored in skin regeneration, particularly with a view of treating the entire skin (and possibly mucous membranes) rather than limited areas of damaged skin (Wagner et al. 2010) .
INHERITED SKIN DISEASES AND THE NEED FOR INNOVATIVE THERAPIES
Epidermolysis bullosa (EB) refers to a group of inherited skin disorders in which blisters develop after relatively minor trauma to the skin. EB results from mutations in at least 18 different genes, mostly encoding structural components of the dermal -epidermal junction (DEJ) or keratinocytes within the lower epidermis (Fine et al. 2008) . Although EB is a rare disease, with an estimated incidence of 1 in 20,000 people, this equates to a worldwide incidence of approximately 500,000 individuals. Collectively, this population has a desperate need for innovative therapies that reduce disease burden, improve quality of life, and make advances toward a cure. In some forms of EB, such as recessive dystrophic epidermolysis bullosa (RDEB), there may be very extensive fragility of the skin and mucous membranes. This profound skin fragility can be associated with delayed wound healing and persistent erosions with longer term complications of scarring and increased incidence of malignancy (Fine and Mellerio 2009a,b) . Recently, considerable progress has been made in developing new treatments for EB, including gene, protein, and drug therapy, although cell therapies have perhaps shown the most clinical translation ). The major challenge is to restore an intact epithelium and provide some protection against mechanical trauma. To that end, therapeutic use of autologous or allogeneic cells, used locally or systemically, is now being explored in clinical trials.
MURINE STUDIES OF FIBROBLAST CELL THERAPY FOR EB
Most murine studies have focused on developing therapies for RDEB in which the underlying pathology involves mutations in the COL7A1 gene encoding type VII collagen (C7), the major structural component of anchoring fibrils at the DEJ. C7 is synthesized and secreted by basal TEN, toxic epidermal necrolysis; ADSC, adipose-derived stem cells; CDS, cultured dermal substitute; GvHD, graft versus host disease; HSCT, hematopoietic stem cell transplantation; MSC, mesenchymal stromal cell; BM, bone marrow; RDEB, recessive dystrophic epidermolysis bullosa; C7, type VII collagen; BMT, bone marrow transplant; JEB, junctional epidermolysis bullosa; QOL, quality of life; RCT, randomized control trial; EBS, epidermolysis bullosa simplex; IM, intramuscular; TBSA, total body surface area; TNC, total nucleated cells; DEJ, dermal-epidermal junction; CEA, cultured epithelial autograft; f/u, follow-up.
Cite this article as Cold Spring Harb Perspect Med 2014;4:a015156 keratinocytes and dermal fibroblasts (Stanley et al. 1985; Regauer et al. 1990; Woodley et al. 2003; Goto et al. 2006; Ito et al. 2009 ). Given that fibroblasts are much easier to isolate and maintain in culture than keratinocytes, fibroblasts present an attractive target for cell-based therapies for RDEB. Normal and COL7A1-gene-corrected human RDEB fibroblasts overexpressing C7 have been injected intradermally into immunodeficient mouse skin or transplanted human RDEB skin equivalents (Ortiz-Urda et al. 2003; Woodley et al. 2003) . Both these interventions led to sustained human C7 deposition and new anchoring fibril formation at the DEJ. It was also shown that intradermal injections of wild-type fibroblasts, that is, without COL7A1-gene correction, could correct the RDEB skin pathology, but only when injected at sufficient cell density (Woodley et al. 2003) . Increase in C7 at the DEJ after intradermal injections of wild-type human fibroblasts was also confirmed in studies using a hypomorphic C7 mouse model of RDEB that expresses C7 at 10% of normal levels (Fritsch et al. 2008; Kern et al. 2009 ). Moreover, intravenously injected wild-type or COL7A1-gene-corrected human RDEB fibroblasts could home to wounded mouse skin and improve wound healing (Woodley et al. 2007) . Collectively, these studies provide a rationale for the use of allogeneic wild-type or COL7A1-gene corrected fibroblasts in human RDEB studies.
FIRST-IN-MAN USE OF FIBROBLASTS IN DYSTROPHIC EB
Based on the mouse data, a proof-of-concept study in five RDEB subjects showed that a single intradermal injection of allogeneic fibroblasts (5 Â 10 6 cells in 25-ml volume injected into the superficial dermis over an 1 cm 2 area) increased COL7A1 gene expression for at least 3 mo (the end point of that study) in most individuals (Wong et al. 2008) . The study also showed the low immunogenicity of allogeneic fibroblasts and lack of host response at an immunological and histological level. The injected cells were not detectable at 2 wk postinjection, the time point at which an increase in C7 protein at the DEJ was seen. Of note, the increase in C7 was most apparent in RDEB subjects who had some baseline expression of C7 compared to those who had a complete absence of the protein. However, the increase in C7 was not accompanied by the formation of new, normal-appearing anchoring fibrils; there was an increase in the number of fibrillar structures below the lamina densa of the basement membrane, but these were somewhat wispy and lacked characteristic ultrastructural features of mature anchoring fibrils. Nevertheless, there was some subjective evidence for increased epidermal -dermal adhesion following the allogeneic fibroblast injections. Given the increase in COL7A1 gene and C7 protein expression beyond the physical presence of the injected allogeneic cells, however, the changes were thought to be caused by a paracrine effect induced by the fibroblasts. A subsequent study was able to show that a single injection of allogeneic fibroblasts could increase COL7A1 gene expression for 3-6 mo and C7 protein for 9-12 mo (Nagy et al. 2011 ).
MODE OF ACTION OF ALLOGENEIC FIBROBLAST CELL THERAPY IN DYSTROPHIC EB
Transcriptomic analysis of serial skin biopsies following injection of allogeneic fibroblasts in one subject with RDEB revealed that expression of heparin-binding epidermal growth factorlike growth factor (HB-EGF) was up-regulated and that expression levels mirrored those seen for the COL7A1 gene (Nagy et al. 2011 ). In vitro studies were able to show that HB-EGF could up-regulate COL7A1 gene expression in both normal-control and RDEB keratinocytes and fibroblasts, and this was preceded by increased expression of JUN and FOS, components of the AP1 transcription factor that are known to bind to and up-regulate COL7A1. The interpretation of the in vivo situation was that allogeneic fibroblasts were able to induce up-regulation of HB-EGF, predominantly in neighboring keratinocytes. The HB-EGF could then lead to a sustained increase in C7 by acting in an autocrine, paracrine, and juxtacrine manner to up-regulate COL7A1. The new C7 was thought to be predominantly recipient-derived, that is, mutant but partially functional. A slight increase in HB-EGF and COL7A1 gene expression was also noted after injection of saline into skin, although up-regulation was less marked than following fibroblast injection and was for a shorter duration. It is also plausible that the donor fibroblasts could release wild-type full length C7 for incorporation into the DEJ during the time (few days) the cells are present in the RDEB skin. Evidence for this "direct release" theory is supported by studies in mice (Kern et al. 2009 ), although both mechanisms are not mutually exclusive. Although often thought as differentiated somatic cells, cultured skin fibroblasts may also contain a subpopulation of cells with stem cell properties, capable of differentiation into mesoderm, endoderm, and ectoderm. Termed MUSE (multilineage-differentiating stress-enduring) cells, these cells are also found in the skin and BM (Wakao et al. 2011 ).
FIBROBLAST CELL THERAPY AND WOUND HEALING IN DYSTROPHIC EB
The initial studies of allogeneic fibroblast injections in RDEB focused on responses at the DEJ in intact skin. However, the major clinical burden in affected individuals is poor wound healing. One randomized double-blind study that assessed the impact of allogeneic fibroblasts in wound healing in RDEB showed no differences in the extent or rate of re-epithelialization of chronic erosions following injection of fibroblasts or inert carrier solution (Venugopal et al. 2013) . In contrast, another clinical trial found that a single injection of allogeneic fibrobalsts can speed up wound healing for 28 d compared to vehicle (Petrof et al. 2013 ). The putative upregulation of HB-EGF following allogeneic fibroblast injection (Nagy et al. 2011 ) may have benefits for wound healing beyond up-regulation of C7, given that HB-EGF has been shown to promote keratinocyte migration (Shirakata et al. 2005) . However, one caveat may be the effects of HB-EGF on epidermal growth factor receptor signaling and risk of malignancy (Zenz et al. 2003) . Given that individuals with RDEB have an increased incidence of squamous cell carcinoma, especially in chronic wounds (Fine and Mellerio 2009a) , further safety monitoring of allogeneic fibroblasts injected into RDEB wounds is required. At the bedside, allogeneic fibroblasts have been used off licence to treat a number of patients with RDEB (Fig. 1) . The clinical impression and experience indicates that for a subgroup of individuals with RDEB, notably those with mild to moderate disease severity and some baseline expression of C7 at the DEJ, allogeneic fibroblast therapy may be useful, in contrast to those individuals with more severe disease that lack C7 expression. For the latter individuals, alternative cell therapy or other strategic approaches may be more effective.
BM STEM CELLS AND THE SKIN
BM stem cells have a fundamental role in generating erythrocytes, leukocytes, and platelets, but also show plasticity in being able to show lineage differentiation into tissues of mesodermal, endodermal, and ectodermal origin, including skin ). Some subpopulations of BM cells can differentiate into keratinocytes (Badiavas et al. 2003a; Borue et al. 2004; Fathke et al. 2004) , and in humans who have undergone bone marrow transplanta- Figure 1 . Intradermal injections of allogeneic fibroblasts promote wound healing in RDEB. A stubborn wound on the side of the neck in this 23-yr-old man with RDEB showed limited improvement and persisting erosions after skin grafting. However, 8 d after fibroblast injection there was significant healing of erosions and improved quality of life; he was able to wear a shirt without discomfort. The clinical benefits of the fibroblast injections lasted for 5 -6 mo.
Cell Therapy in Dermatology
Cite this article as Cold Spring Harb Perspect Med 2014;4:a015156 tion (BMT), donor cells that have differentiated into keratinocytes can be detected in the epidermis for at least 3 yr (Korbling et al. 2002) . Further studies have shown that the BM is also a source of fibroblast-like cells in the dermis (of hematopoietic and mesenchymal lineages) and that the number of these cells increases after skin wounding (Fathke et al. 2004; Ishii et al. 2005; Sasaki et al. 2008) . BM cells also contribute to skin development; infusion of BM cells in utero in mice leads to accumulation of a subpopulation of these cells in the dermis, particularly around developing hair follicles (Chino et al. 2008) . Overall, however, BM-derived keratinocytes appear to be an extremely rare finding, perhaps contributing only 0.0001% -0.0003% of all cells in the new epidermis (Tamai et al. 2011 ). The physiological role of BM cells in epithelial regeneration therefore has been questioned, although recent studies focusing on RDEB have started to provide new insight into key BM cells and mechanisms germane to skin repair and regeneration.
MURINE STUDIES OF BM CELLS AND SKIN REPAIR
Initial attempts to use BM cells to correct the inherent skin fragility of RDEB were made in the Col7a1 knockout mouse that recapitulates some of the features of the human disease (Heinonen et al. 1999; Tolar et al. 2009 ). Nonmanipulated BM failed to rescue the RDEB mice, but alternative use of the signaling lymphocyte activating molecule (SLAM)-positive subpopulation of BM cells resulted in new C7 and presence of donor cells at the DEJ. Following infusion of SLAM-positive BM cells, there was improved healing of blisters on the mouth and paws, and histological evidence of rudimentary anchoring fibril formation (Tolar et al. 2009 ). Other studies have also shown correction of RDEB skin defects with BM cells (Fig. 2) , that repair can occur after in utero infusion of BM cells (Chino et al. 2008) , and BM-derived mesenchymal stromal cells (MSCs) can stimulate secretion of C7 with partial restoration of the damaged basement membrane zone and less blister formation (Alexeev et al. 2011) . In a different mouse that lacks type XVII collagen, a model for non-Herlitz junctional EB, both hematopoietic and nonhematopoietic BM stem cells have been shown to correct basement membrane protein expression and lead to phenotypic rescue (Fujita et al. 2010 ). Collectively, these murine studies provide a scientific rationale for translation of BM cell therapies into human clinical trials. Moreover, several additional mouse models for different forms of EB have been developed recently that will also be useful for assessing BM cell therapy, including the hypomorphic C7 mouse (Fritsch et al. 2008 ) and a hypomorphic model for non-Herlitz junctional EB with a spontaneous mutation in the Lamc2 gene (Bubier et al. 2010 ).
FIRST-IN-MAN STUDIES OF MSC THERAPY IN DYSTROPHIC EB
The use of intradermal MSC therapy was first reported in two patients with RDEB in 2010 (Conget et al. 2010) , although successful topical use of BM cells to heal chronic wounds in other diseases has been reported previously (Badiavas and Falanga 2003b; Humpert et al. 2005; Falanga et al. 2007 ). The MSCs used in the RDEB study were derived from the BM of a healthy, unrelated individual. The RDEB subjects had a complete Figure 2 . BM cells can correct lack of C7 in RDEB mouse skin. Grafting of mouse skin lacking C7 onto a mouse with green fluorescent BM leads to some BM cells entering the epidermis and follicular epithelium. Moreover, new basement membrane C7 (red) is noted in proximity to these green cells. Scale bar, 25 mm. (This figure is based on data reported by Tamai et al. 2011.) absence of C7 expression at the DEJ on immunofluorescence microscopy and clinically had severe blistering and wounds that healed slowly with scarring. The investigators injected 0.5 Â 10 6 MSCs or vehicle into both intact and chronically ulcerated sites (Fig. 3) . Skin biopsy was performed 1 wk after intervention and showed that the MSC-treated skin expressed C7 at the DEJ. Moreover, there was re-epithelialization of chronically ulcerated skin near the MSC injection site, but not near the vehicle injected site. Both patients in the study showed clinical benefits that lasted for 4 mo. Thereafter, the skin fragility resembled the pretreatment state. No adverse effects were noted in the injected skin or systemically. This pilot study showed that the intradermal administration of allogeneic MSCs can lead to de novo C7 expression at the DEJ as well as preventing blistering and improving wound healing in patients with RDEB. A clinical trial using intravenous unrelated donor BMderived MSCs in subjects with RDEB has recently been performed (M El Darouti, pers. comm., 2012) . Although no skin biopsies were performed in that study, clinical evaluation reported a reduction in the number of blisters, less skin inflammation, better wound healing, and improved quality of life, which lasted for 4 -6 mo following a single infusion of MSCs. Further evaluation of systemic MSCs in RDEB is anticipated.
BMT IN DYSTROPHIC EB
Following the effectiveness of BM stem cells in murine RDEB, a clinical trial of whole BMT was performed in children with RDEB (Wagner et al. 2010) . The approach used high-dose chemotherapy to immunoablate individuals with RDEB to permit more reliable lymphohematopoietic engraftment. The BM was not filtered so that all the hematogenous populations could be preserved, allowing for the possibility that nonhematopoietic MSC populations might also be needed for clinical benefits. Seven patients entered the trial and six underwent BMT. All individuals had some clinical improvement and five of the six showed increased C7 at the DEJ (Fig.  4) . The first patient in the trial is now 5 yr since transplantation. Before the BMT, each individual had more than 50% of their skin covered with blisters and erosions. Three of the six individuals showed a dramatic clinical improvement, such that ,10% of the body surface area remained affected. In the other three subjects, there was a moderate improvement with less than 25% of the body surface area affected. Despite the clinical improvement, some toxicity was noted. One patient died before the BMT because of heart failure, possibly related to cyclophosphamide toxicity and pre-existing renal failure. Another individual died 6 mo after transplantation because of infection secondary to graft failure. Translational research is now attempting to refine BMT protocols to consider use of reduced intensity conditioning and perhaps subpopulations of BM cells once mechanisms of action in repairing defective EB skin 
MODE OF ACTION OF SKIN REPAIR IN DYSTROPHIC EB FOLLOWING BMT
The precise mode of action of BMT leading to clinicopathological improvement in RDEB is not known. High levels of chimerism (donor and recipient cells) were noted in skin after BMT, with donor nonhematopoietic cells being the probable source of new C7 at the DEJ. Notably, although there were some hematopoietic cells in the skin (CD45 þ ), the majority were nonhematopoietic, nonendothelial cells (CD45 -,CD31 -). In spite of the increased C7, however, there was a lack of normal anchoring fibrils on transmission electron microscopy. Although the lack of these adhesion structures may relate to gradual maturation of new anchoring fibrils (as has been observed for several months following burns), it is plausible that some of the increased C7 may reflect an up-regulation of mutant but partially functional endogenous C7, similar to the proposed mode of action for allogeneic fibroblast therapy. Clearly, however, there is more to the reparative story in that the transplanted RDEB patient who did not show any increase in C7 also showed a sustained clinical response in skin healing and integrity at the DEJ. This may indicate the incorporation or availability of additional extracellular matrix proteins that can contribute to better skin repair and adhesion, although such a possibility remains speculative. Functional improvement in skin adhesion in patients following BMT was shown by progressive increases in suction blister times (the time it takes to form a blister following placing a negative-pressure suction cup on the skin surface). Although mode of action of BMT in skin repair in EB continues to be investigated, current clinical data provide evidence for a sustained functional improvement in the majority of patients.
EPITHELIAL PROGENITORS WITHIN SUBPOPULATIONS OF BM STEM CELLS
A recent study has shown that BM contains a specific population of epithelial progenitors and Figure 4 . Whole BMT results in clinicopathological correction of the skin pathology in RDEB. This 15-mo-old child shows a marked improvement with healing of chronic wounds and fewer blisters 100 d after BMT. There is also increased C7 at the DEJ (arrows). Scale bar, 25 mm. (The original images were kindly provided by Dr. Jakub Tolar, based on data reported by Wagner et al. 2010.) that these are mobilized and recruited by certain key factors. Tamai et al. (2011) used an irradiated mouse model in which green fluorescent protein-labeled BMT was performed. Subsequent skin grafting in this mouse was able to identify that BM-derived keratinocytes are not of hematopoietic origin, but instead are derived from a specific subpopulation of lineage-negative, platelet-derived growth factor receptor apositive (Lin 2 /PDGFRa þ ) BM cells. This is still a somewhat heterogeneous cell population that represents approximately 1 in 450 BM cells. Indeed, these cells may show lineage overlap with other defined subpopulations of MSCs, including multipotent adult progenitor cells,
2 unrestricted somatic cell stems in cord blood, and nestin-positive cells that maintain the stem cell niche with hematopoietic stem cells in BM. The study by Tamai et al. (2011) proposed that the skin graft acted as a hypoxic bioreactor, rapidly releasing the nonhistone nuclear protein high-mobility group box-1 (HMGB1). Following skin grafting, HMGB1 levels in serum increased and HMGB1 was shown to mobilize these cells along an HMGB1 concentration gradient to the area of hypoxic keratinocytes. Differentiation of these cells into keratinocytes was clearly shown. The study also showed that in RDEB the main source of HMGB1 was hypoxic keratinocytes in blister roofs. The implication of this study is that there is a subpopulation of nonhematopoietic BM cells comprising 0.22% of the BM population that has the capacity to restore defective epithelium, including targeting and correcting the pathology of RDEB.
BMT FOR OTHER INHERITED SKIN DISEASES
BMT has been used as a form of stem cell therapy for more than 40 years and is really the only stem cell therapy with a definite therapeutic benefit. Although the initial applications were for leukemia, lymphoma, aplastic anemia, and hemoglobinopathies, the clinical indications for BMT have expanded and approximately 50,000 people worldwide have received this form of therapy. As well as clinical trials in RDEB, BMT is being investigated in other forms of EB including Herlitz junctional EB (Tolar et al. 2012b) . One further consideration in Herlitz junctional EB, however, is that the defective protein (laminin-332) is not synthesized by fibroblasts (unlike C7); it is only generated by keratinocytes. Thus, whether corrective donor cells in the dermis can secrete the defective basement membrane protein is uncertain. Perhaps correction of epithelial cells is essential in this form of EB. Nevertheless, early studies have indicated that BMT may increase laminin-332 expression at the DEJ in some individuals. It is still too early, however, to reflect on the clinical indications and possible benefits from this treatment. The same caveats exist for epithelial synthesized proteins germane to non-Herlitz junctional EB in which either laminin-332 or type XVII collagen may be defective, although the clinicopathological improvement seen in type XVII collagen-deficient mice after BM cell therapy provides some justification for human studies (Fujita et al. 2010) . Gradually, therefore, it seems likely that other forms of EB associated with severe morbidity may be evaluated in clinical trials of BMT. Conceptually, this form of cell therapy should still be regarded as a highly experimental procedure.
UMBILICAL CORD BLOOD TRANSPLANTATION AND THE SKIN
Cord blood (CB) and other parts of the umbilical cord, such as the Wharton's jelly or tissues associated with the placenta, are rich sources of stem cells. Like hematopoietic stem cells, CB is an important source of other progenitor cells, as well as MSCs, very small embryonic-/epiblast-like stem cells and unrestricted somatic stem cells, which may have individual or collective value in regenerative medicine. Using some stem cell populations, notably the MSCs, a number of clinical studies have been initiated, mostly to repair tissue, including some studies on skin. The first transplant in humans using CB was reported in 1989 with the use of human leukocyte antigen-matched sibling CB to treat Fanconi anemia (Gluckman et al. 1989 ). Subsequently, CB banks were established for the collection and cryopreservation of cells and more than 20,000 CB transplants have been performed worldwide. MSCs from CB are similar to BM-derived MSCs in having low immunogenicity and are already being used in several studies of regenerative medicine. That said, comparison of umbilical cord cells versus BM stem cells in individuals with RDEB has shown better skin engraftment with a BM-derived population (Tolar et al. 2012a ) and, therefore, the clinical utility of cord cells in EB or other skin disorders remains to be determined in future clinical trials. Recent, preclinical data, however, have shown that unrestricted somatic stem cells can express C7 and accelerate wound healing, including improving the quality of wound healing, as evidenced by formation of new skin appendages (Liao et al. 2013) .
REVERTANT MOSAICISM AND SPONTANEOUS NATURAL CELL THERAPY
One striking observation in recent years has been that some patches of skin in patients with various inherited skin diseases can undergo spontaneous correction of the genetic defect underlying the skin pathology, a concept known as revertant mosaicism or "natural gene therapy." This was first noticed in the late 1990s in a patient with non-Herlitz junctional EB resulting from autosomal recessive mutations in type XVII collagen (Jonkman et al. 1997) . Revertant mosaicism is a naturally occurring process characterized by spontaneous genetic repair that can lead to a partial or complete reversal of an affected to a wild-type phenotype (Fig. 5) . In addition to non-Herlitz junctional EB, other variants of EB including EB simplex, RDEB, and Kindler syndrome have all shown evidence of revertant mosaicism . Likewise, skin diseases such as ichthyosis with confetti and dyskeratosis congenita have also been shown to display this phenomenon. Indeed, a recent study has suggested that in vivo reversion may occur in all patients with generalized non-Herlitz junctional EB (Pasmooij et al. 2012) . The predominant mechanisms of gene correction include back mutation, gene conversion, intragenic recombination, and second-site mutation. The genetic correction appears to Figure 5 . Revertant mosaicism represents a form of natural gene therapy in RDEB skin. This 40-yr-old man with RDEB has a patch of skin on his right shin that does not blister (unlike the surrounding skin that blisters after minor trauma). Skin from the reverted area shows near-normal intensity C7 immunoreactivity at the DEJ in contrast to the complete absence of C7 in the unreverted skin. Scale bar, 25 mm. (Images are based on data reported by Almaani et al. 2010.) be limited to keratinocytes rather than fibroblasts or other cell populations, perhaps reflecting higher proliferation rates in keratinocytes (Jonkman et al. 1997) . The main clinical consequence of revertant mosaicism is the phenotypic improvement of disease, although the timing of the reversion may influence the extent of revert mosaicism and the severity of the condition, that is, early reversion of events during embryonic development is more likely to result in larger revertant patches.
REVERTANT CELL THERAPY FOR EB
The opportunity to expand keratinocytes derived from a patch of revertant mosaicism creates a translational opportunity for revertant cell therapy that is personalized and patient specific. The key advantage of this approach is that the cells are naturally corrected and, therefore, additional genetic manipulation should not be necessary. The first attempt at revertant cell therapy was reported in an individual with revertant mosaicism in non-Herlitz junctional EB (Gostynski et al. 2009 ). Revertant keratinocytes from this patient were isolated, expanded into epidermal sheets, and grafted onto a de-epidermized area of mutant skin. In culture, 30% of keratinocytes displayed reversion, but, for reasons unknown, fewer than 3% of the corrected cells persisted in the graft and thus clinically, the graft remained fragile and skin integrity did not improve. This case provided proof-of-principle about the feasibility of revertant cell therapy, but showed that further optimization would be required for successful transplantation. Future improvements in graft production and maintenance of reversion in culture might lead to better function in future attempts at skin transplantation. An alternative approach might be to use pinch/punch grafting using skin from the revertant patches and transplanting these pieces of "normal" skin into affected areas within the same individual. For example, this may be clinically useful if reverted skin was seeded adjacent or within chronic erosions to promote wound healing. Whether creating minor injury to the edge of a patch of revertant mosaicism would lead to expansion of area of reverted keratinocytes is not known; most patches of reversion tend to enlarge initially, but then remain static (Lai-Cheong and McGrath 2013) . Although fibroblast culture is considerably easier than keratinocyte culture (especially in patients with EB), the lack of demonstrable revertant mosaicism in fibroblasts means that revertant cell therapy is not possible with this cell population.
FUTURE CELL THERAPY STRATEGIES: I. REFINEMENT OF EXISTING BM CELL PROTOCOLS
Although the majority of RDEB children who participated in the initial BMT trial showed remarkable clinical benefit, two of seven children died (one before BMT) (Wagner et al. 2010) . To try to reduce morbidity and mortality, additional protocols have been developed to use reduced intensity conditioning rather than full myeloablation. Modifications to the original protocol, such as the additional subsequent infusion of MSCs from the original donor, have also been adopted. A further issue is whether to use a subpopulation of cells that can specifically repair skin and mucous membranes. For example, use of the Lin 2 /PDGFRa þ MSCs that were previously shown to harbor epithelial progenitors might be suitable (Tamai et al. 2011) . Another consideration may be just to use allogeneic MSCs, as has been trialed in several other diseases because of their anti-inflammatory properties. MSCs can home to damaged tissue and release various immunomodulatory factors that influence the behavior of dendritic cells, T cells, and natural killer cells. MSCs can reduce Bcell proliferation, monocyte maturation, secretion of IFN-g and TNF-a while promoting induction of T-regulatory cells and secretion of anti-inflammatory IL-10 from macrophages in direct contact with MSCs. Although the precise microenvironmental contributions to tissue repair are not fully known, a more detailed understanding of the trophic mechanisms associated with MSCs in tissue regeneration is likely to lead to further exploration of clinical utility. In general, whatever immune conditioning or cell population is being planned for use as cell therapy, for diseases such as EB, it is evident that treatment that is both systemic and given at an early age is likely to have the most clinical benefit, certainly for patients with widespread disease.
FUTURE CELL THERAPY STRATEGIES: II. TARGETING OF SUBPOPULATIONS OF BM CELLS TO DAMAGED SKIN
The murine wound healing studies performed by Tamai et al. (2011) provide some insight into how skin grafting may work. Grafting a split thickness or full thickness piece of skin to ulcers and burns is widely used in clinical practice and the benefits may be derived from direct restoration of a covering skin barrier. A further reparative mechanism, however, might be through local release of HMGB1 into the circulation with recruitment of Lin 2 /PDGFRa þ cells from the BM. Large skin grafts might release sufficient HMGB1 into the sera to reach a threshold that is sufficient to mobilize this subpopulation of MSCs from BM. Smaller skin grafts that do not release sufficient HMGB1 to reach threshold would not be expected to have the capacity to mobilize these cells unless additional local or systemic HMGB1 was given. The recruitment of Lin 2 /PDGFRa þ cells to a skin graft may be dependent on the gradient of HMGB1 (i.e., the local skin levels initially being greater than those in the serum). Although patients with RDEB have been shown to have increased HMGB1 in their blister fluid (released from the damaged keratinocytes in the blister roof ) and serum (Tamai et al. 2011) , it is not known whether this elevated HMGB1 can mobilize the Lin 2 / PDGFRa þ cells from the patient's BM, or whether there may be some partial or complete exhaustion of these cells because of the chronic subepidermal skin blistering. BMT strategies aimed at restoring this cell population or promoting targeting of these particular MSCs in patients with RDEB may be helpful in tissue repair, including mobilization of these MSCs from BM or recruitment to damaged skin being augmented by use of recombinant HMGB1. These MSCs may also represent an additional attractive target for COL7A1 gene therapy.
FUTURE CELL THERAPY STRATEGIES: III. COMPLEMENTARY APPROACHES WITH COMBINATION GENE THERAPY
Although phase I/II clinical trials of cell therapy in EB have been initiated, it is clear that the ideal therapy for EB is unlikely to involve just allogeneic cells. More likely to be clinically useful is a combination of gene, protein, drug, and cell therapies. To that end, some progress is being made, although so far, only one proof-of-principle study has been published using somatic gene therapy in EB (Mavilio et al. 2006) . In that study, a retroviral vector was used to insert the LAMB3 transgene into autologous keratinocytes that were then grafted back as a confluent sheet onto the thigh of an adult male with nonHerlitz junctional EB. One key practical problem was the lack of holoclone stem cells in the patient, which was probably a consequence of long-term skin blistering. Over the subsequent 6 yr, however, the graft has continued to express laminin-332 at the DEJ with functional improvement and lack of blistering. Other studies of gene therapy, notably for RDEB, are at preclinical or early clinical stages mostly involving ex vivo keratinocyte grafting following introduction of a transgene or correction of both keratinocytes and fibroblasts and construction of a skin equivalent. Whether keratinocytes are the ideal cell to target, however, is debatable. Local gene therapy might involve genetic correction of autologous fibroblasts with the reparative transgene, an approach that might avoid the probable pitfalls of wound infection and graft loss using a topical approach in RDEB. Alternatively, if systemic gene therapy is used, it may be more appropriate to target BM cells that include epithelial progenitors or cells that can contribute to skin repair.
FUTURE CELL THERAPY STRATEGIES: IV. COMPLEMENTARY APPROACHES WITH COMBINATION PROTEIN AND DRUG THERAPIES
With regard to protein therapy, this has also been tested with recombinant C7 in small and large animal models of RDEB (Palazzi et al. 2000; Woodley et al. 2013) . Initial studies used C7-null mice showed that intradermally injected recombinant C7 resulted in linear organization of C7 at the DEJ and formation of anchoring fibrils (Remington et al. 2009 ). Subsequent intravenous infusion of recombinant C7 was shown to home to wounds in murine RDEB models and restore C7 expression and function. Subsequently, a naturally occurring RDEB dog model has been used to test intravenous protein therapy (Palazzi et al. 2000) .
Although not yet at a clinical stage, it is likely that intradermal, and possibly intravenous, delivery of C7 will transfer into clinical trials shortly. It is also likely that some individuals with EB will benefit from a new group of compounds that have the capability of inducing readthrough of nonsense mutations (Arakawa et al. 2003; Cardno et al. 2009 ). Several recessive forms of EB involve loss-offunction mutations. Notably, in RDEB, 15% of all pathogenic mutations involve nonsense mutations (Dang and Murrell 2008) and these are likely to be a focus for readthrough therapeutics. Such drugs can increase mRNA expression by 5% -10%, leading to increased protein synthesis (Rowe and Clancy 2009) . Given that mouse models of RDEB have indicated that it is necessary to have 30% -40% of normal levels of C7 at the DEJ to prevent blistering (Fritsch et al. 2008; Kern et al. 2009 ), the use of a systemic readthrough drug in appropriate patients may help contribute toward this target and complement other therapies.
FUTURE CELL THERAPY STRATEGIES: V. COMBINING REVERTANT MOSAICISM WITH INDUCIBLE PLURIPOTENT STEM CELL TECHNOLOGIES
One potentially exciting future translation that exploits the therapeutic potential of revertant keratinocytes in different forms of EB and other diseases may be to combine the natural phenomenon of revertant mosaicism with recent stem cell biology techniques, specifically in the creation of inducible pluripotent stem cells (iPSCs). This could be an extremely attractive option because it would avoid the potential genotoxic risk of retroviral vectors needed for gene therapy. Spontaneously corrected cells for iPSC generation that are derived from revertant keratinocytes avoid the need for further genetic correction. With regard to the skin, iPSCs have recently been generated from keratinocytes isolated from patients with RDEB and fibroblasts derived from individuals with Herlitz junctional EB (Bilousova et al. 2011; Itoh et al. 2011; Tolar et al. 2011 Tolar et al. , 2013 . One translational vision might be to create a bank of iPSCs to differentiate into skin cells for repairing skin wounds, but there are other options. Specifically, one possibility might be to differentiate these cells into the MSCs that contain the population of epithelial progenitors recently identified in BM. These Lin 2 /PDGFRa þ cells could be given locally to wounded skin to augment wound healing responses. Alternatively, the cells could be given systemically and might be expected to home to areas of hypoxic skin (i.e., wounds) or reside in BM until a future episode of skin trauma occurs, at which time they would be mobilized and recruited to that damaged, hypoxic site. Clinical use of iPSCs in dermatology has not yet been achieved, but remains a future option for consideration.
CONCLUDING REMARKS
Having the capacity and technical ability to culture and expand human keratinocytes and fibroblasts has led to the widespread use of skin grafts to treat chronic wounds and ulcers in both inherited and acquired diseases. Although further refinements in bioengineering and construction of skin grafts are likely to lead to additional clinical benefits for patients, the concept and application of cell therapy for skin diseases recently has expanded to encompass other aspects of regenerative medicine. For inherited skin diseases, the potential to harness and exploit the potential of natural phenomena such as revertant mosaicism (revertant cell therapy), or the plasticity of BM cells to regenerate skin, provide exciting new opportunities to further develop cell therapy in dermatology. Moreover, emerging technologies such as the creation of iPSCs offer an even broader horizon to help deliver clinical benefits from regenerative medicine in dermatology.
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